Skip to main content
Contact Us
Subscribe
E-Edition
68°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyadic International
(NQ:
DYAI
)
1.140
+0.050 (+4.59%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyadic International
< Previous
1
2
3
4
5
6
Next >
“Revolutionizing Biotechnology: Dyadic International (NASDAQ: DYAI) Leads with C1 Platform for Swift and Efficient Protein Production”
January 11, 2024
Via
AB Newswire
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
January 05, 2024
Via
AB Newswire
“Dyadic International Inc. (NASDAQ: DYAI): Zacks Small-Cap Research Indicates Valuation at $9.00 per Share”
January 05, 2024
Via
AB Newswire
“Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development”
January 02, 2024
Via
AB Newswire
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024
From
Dyadic International, Inc.
Via
GlobeNewswire
Recap: Dyadic International Q3 Earnings
November 08, 2023
Via
Benzinga
“2024 Market Outlook: SmallCap Radar Stocks Unveiled”: DYAI, SKYX, QUBT, KNW, VTAK
December 28, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
December 21, 2023
Via
AB Newswire
Exposures
COVID-19
CryptoNewsBreaks – Innovators and Ideas Showcased at 12th Annual Benchmark Discovery Conference
December 19, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Standouts from 12th Annual Benchmark Discovery Conference Featured in Nasdaq Article
December 13, 2023
Via
Investor Brand Network
Dyadic Attends Investor Events in December
November 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 29, 2023
Via
Benzinga
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
November 20, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry Events in November
October 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Appoints Doug Pace to Its Executive Leadership Team
October 09, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 05, 2023
Via
Benzinga
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
October 05, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry and Investor Events in October
September 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at BioProcess International
September 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Upcoming Events in June
June 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Two Industry Events in May
May 10, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
